The immunoregulatory role of type I and type II NKT cells in cancer and other diseases

By Terabe Masaki   Berzofsky Jay  

Cancer Immunology, Immunotherapy, Vol. 63, Iss. 3, 2014-03 ,pp. : 199-213

Springer Publishing Company

Access to resources Recommend Favorite

Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 6, Iss. 5, 2006-09 ,pp. : 451-460

Bentham Science Publishers

Access to resources Recommend Favorite

Breast cancer associated with type 1 neurofibromatosis

By Salemis Nikolaos  

Breast Cancer, Vol. 17, Iss. 4, 2010-10 ,pp. : 306-309

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer

By Tecimer C.   Doering D.L.   Goldsmith L.J.   Meyer J.S.   Abdulhay G.   Wittliff J.L.  

Gynecologic Oncology, Vol. 80, Iss. 1, 2001-01 ,pp. : 48-55

Elsevier

Access to resources Recommend Favorite

A Phase I/II Trial of Radiotherapy Concurrent with TS-1 Plus Cisplatin in Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1205

By Imano Motohiro   Furukawa Hiroshi   Yokokawa Masaki   Nishimura Yasumasa   Kurokawa Yukinori   Satoh Taroh   Sakai Daisuke   Yasuda Takushi   Imamoto Haruhiko   Tujinaka Toshimasa   Shimokawa Toshio   Shiozaki Hitoshi  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 4, 2013-04 ,pp. : 431-435

Oxford University Press

Access to resources Recommend Favorite